CCI approves GlaxoSmithKline, Pfizer consumer healthcare joint venture

The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer

Press Trust of India May 24, 2019 14:19:03 IST
CCI approves GlaxoSmithKline, Pfizer consumer healthcare joint venture
  • GSK, in December 2018, had said it has reached an agreement with Pfizer to combine their consumer health businesses into a new joint venture (JV) with combined sales of around $12.7 billion (around Rs 88,900 crore)

  • After the deal, GSK will have a majority controlling equity interest of 68 percent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 percent

  • In a tweet, the Competition Commission of India (CCI) said it approves the formation of a JV for consumer healthcare products by GSK and Pfizer

New Delhi: The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.

GSK, in December 2018, had said it has reached an agreement with Pfizer to combine their consumer health businesses into a new joint venture (JV) with combined sales of around $12.7 billion (around Rs 88,900 crore).

In a tweet, the Competition Commission of India (CCI) said it "approves the formation of a JV for consumer healthcare products by GSK and Pfizer."

CCI approves GlaxoSmithKline Pfizer consumer healthcare joint venture

Representational image. Getty.

The proposed combination involves the acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK, as per a notice submitted to CCI.

After the deal, GSK will have a majority controlling equity interest of 68 percent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 percent.

In the consumer healthcare segment, GSK is active in research, development, manufacturing, and marketing of products which are typically available without a prescription (over-the-counter) for various indications.

On the other hand, Pfizer's consumer healthcare segment develops, manufactures and markets non-prescription medicines, vitamins, and nutritional products.

GSK had said that the transaction is expected to close in the second half of 2019, subject to approval by its shareholders and certain antitrust authority approvals.

GSK is a British pharmaceutical company headquartered in London, whereas Pfizer is a US-based firm with headquarters in New York.

Updated Date:

also read

What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India
India

What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India

Given that Pfizer's mRNA vaccine is the only jab to have been approved for use in children aged 12 and 17, the 50 million doses the govt aiming to procure should be allow India vaccinate most of its children in that age group

European agency EUA clears Moderna COVID-19 vaccine for children aged 12 to 17 years
Health

European agency EUA clears Moderna COVID-19 vaccine for children aged 12 to 17 years

In a decision on Friday, the EU drug regulator said research in more than 3,700 children aged 12 to 17 showed that the Moderna vaccine already given the OK for adults across Europe produced a comparable antibody response.